Previous Blogs

Analytical Lab Testing

By Jia Min Boo

August 06, 2020

In 2011, the US FDA issued an advisory regarding the potential formation of glass lamellae in vials containing injectable drugs. This was in response to several drug recalls in 2010-11. The number of glass-related drug recalls has since declined greatly. This no doubt is due to key actions taken by pharmaceutical manufacturers before the drug goes to market, even during the development phases.

Blue West logo with Diamond

By Global Communications

March 11, 2015

West Pharmaceuticals will participate in two poster presentation sessions at the Parenteral Drug Association (PDA) Annual Meeting, taking place March 16-18, 2015 in Las Vegas. During the meeting, West will also showcase innovations in integrated drug packaging and delivery systems that help ensure the quality, safety and efficacy of injectable drug products for pharmaceutical and biotechnology manufacturers worldwide at booth #405.

Blue West logo with Diamond

By Global Communications

July 11, 2013

Even though glass syringes are predominantly used for primary containment of parenterals, the (bio)pharmaceutical industry continues to cope with certain limitations associated with glass containment systems. This is especially true when the drug is administered via prefilled drug-delivery systems such as auto-injectors or pens where glass cracks and breakage can be a serious risk for patients.